"If you're in the
hospital's situation, you're going buy the drug that's the lowest cost that
your pharmaceutical therapeutics committee prefers. You're not going to want to
refrigerate a couple items that had a potential risk of a refrigerator
breaking, and now you lose a million bucks."
— Brian Anderson, a principal at Milliman Inc., spoke with AIS's
RADAR on Drug Benefits
about how drugmakers can work to increase biosimilar competition and formulary
uptake, and what obstacles can get in the way.
Subscribers may read the RADAR on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.
No comments:
Post a Comment